Acelyrin, Inc. (SLRN): Multiplikator Forward P/S
Can Acelyrin, Inc. (SLRN) scale the expansion of its immunology pipeline? This forward P/S chart provides the answer, where the value describes the current level. Revenues are based on izakibept sales to psoriasis patients via insurance networks, while the digitization of clinical test data for the interleukin inhibitor is now performed using software robots and precision manipulators.
SLRN (ACELYRIN Inc.): rincian analitis lan laporan miturut indikator
- rega saiki lan proyeksi nilai saham:
- data kapitalisasi bursa:
- statistik nilai buku emiten:
- data tingkat utang lan likuiditas finansial:
Rasio Total Utang marang Ekuitas Acelyrin, Inc.|SLRN - Kewajiban jangka dawa marang modal|Utang jangka cendhak marang ekuitas Acelyrin, Inc.|SLRN - Kewajiban utang agregat|Utang-utang marang kapitalisasi buku ACELYRIN Inc.|SLRN - Gunggunge utang jangka dawa|Utang jangka cendhak perusahaan ACELYRIN|Indikator likuiditas cepet acelyrin.com
- rincian asil keuangan lan kelipatan valuasi:
SLRN - Bathi pungkasan|Proyeksi bathi mangsa ngarep Acelyrin, Inc.|SLRN - Periode bali modal bisnis|Rega marang bathi mangsa ngarep ACELYRIN, Inc.|SLRN - Rasio P/E diaturake wutah|Pangali EV/EBITDA ACELYRIN Inc.|SLRN - Bathi operasional sadurunge ngurangi amortisasi|Bathi resik saben saham sajrone 12 wulan pungkasan ACELYRIN|SLRN - Bathi resik saben saham sajrone patang kuartal pungkasan|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan acelyrin.com|SLRN - Prakiraan wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Acelyrin, Inc.
- rincian pendapatan lan dodolan:
Ringkesan analisis perusahaan:ACELYRIN SLRN
For the biopharmaceutical sector of Acelyrin, Inc. (SLRN), where capitalization is based on expectations from Phase 3 trials, it is critically important to correlate market value with expected cash flow. By analyzing the forward revenue multiple, an investor assesses the ratio of the current share price to future sales, which allows for the timely recognition of asset overheating against a backdrop of high cash burn and fierce competition from pharma behemoths.
Analisis perusahaan pesaing
Multiplikator Forward P/S HLN (Haleon)|Multiplikator Forward P/S Kenvue Inc KVUE|Verona Pharma Corp - Multiplikator Forward P/S|Jyong Bio (MENS) - Multiplikator forward rega marang pendapatan|LGND: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep amneal.com (AMRX)|Rasio rega marang prakiraan pendapatan Perrigo|Rasio rega marang prakiraan pendapatan ALVO|Multiplikator forward rega marang pendapatan LQDA (Liquidia Technologies)|GLPG - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Rasio rega marang prakiraan pendapatan ANI Pharmaceuticals ANIP|Rega forward marang dodolan MNKD|Amphastar Pharmaceuticals, Inc. - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Pacira Pharmaceuticals PCRX|ARS Pharma (SPRY) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan TBPH|Multiplikator forward rega marang pendapatan AQST|SCPH: Rega forward marang dodolan|Multiplikator Forward P/S TECX|Rasio kapitalisasi marang dodolan sing dikarepake Tonix Pharma|Rasio rega marang prakiraan pendapatan China SXT Pharmaceuticals, Inc. SXTC|EPRX: Kapitalisasi marang prakiraan pendapatan|BioHarvest Sciences - Multiplikator Forward P/S|invizyne.com (EXOZ) - Multiplikator forward rega marang pendapatan|ORMP (oramed.com) - Multiplikator forward rega marang pendapatan|ENTX - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan MindWalk|ABVC BioPharma, Inc (ABVC) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Cumberland Pharmaceuticals (CPIX)|Rasio rega marang prakiraan pendapatan QNTM (quantumbiopharma.com)|Rasio rega marang prakiraan pendapatan FibroGen FGEN|Rega forward marang dodolan TELO|RANI - Rasio rega marang prakiraan pendapatan|SNYR (Synergy CHC Corp) - Kapitalisasi marang prakiraan pendapatan|rallybio.com (RLYB) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan LEXX (Lexaria Bioscience Corp.)|PULM (Pulmatrix) - Multiplikator Forward P/S|PTHL: Rega forward marang dodolan|Multiplikator Forward P/S APM|Multiplikator Forward P/S Lyra Therapeutics Inc (LYRA)|Rasio rega marang prakiraan pendapatan Impact BioMedical Inc IBO|Rega forward marang dodolan TNFA|YCBD - Rasio rega marang prakiraan pendapatan|PainReform Ltd (PRFX) - Multiplikator forward rega marang pendapatan|CYTO: Multiplikator Forward P/S|Lipella Pharma (LIPO) - Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan OPTN|PIRS: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Procaps (PROC)|PTPI - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Qilian International Holding Group Limited - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake TFFP (TFF Pharmaceuticals, Inc)
